ProteoNic Announces Licensing of Technology for Production of Biologics to Immunomedics, October 20, 2020

LEIDEN, Netherlands, Oct. 20, 2020 /PRNewswire/ — ProteoNic BV, a leading provider of technology and services in the field of production of biologics, today announced it has licensed its premium 2G UNic™ technology for boosting therapeutic protein production to Immunomedics, Inc. (NASDAQ: IMMU), a biopharmaceutical company developing immuno-therapeutics for the treatment of cancer and other diseases. Under the agreement,…

Cytovia Therapeutics Licenses ProteoNic Technology, August 19, 2020

Cytovia Therapeutics Licenses Productivity-Boosting Manufacturing Technology for Its NK Engager Multifunctional Antibodies From ProteoNic Cytovia developing novel CAR NK cell therapy and NK engager antibodies for cancer   August 12, 2020 09:04 ET | Source: Cytovia Therapeutics NEW YORK and LEIDEN, the Netherlands, Aug. 12, 2020 (GLOBE NEWSWIRE) — Cytovia Therapeutics, Inc (Cytovia), an emerging biopharmaceutical company developing…

ProteoNic Biotechnology licenses Protein Production technology to Bayer

Leiden, the Netherlands, March 28, 2019. ProteoNic Biotechnology BV today announced that it has licensed its 2G UNic™ technology for boosting recombinant protein production to the pharmaceutical company Bayer.
Under the agreement, Bayer gains non-exclusive, worldwide commercial rights for application of the technology to the development of its proprietary products. Financial details of the agreement were …

ProteoNic Biotechnology licenses Protein Production technology to Eli Lilly and Company

Leiden, the Netherlands, Feb 5, 2019.  ProteoNic Biotechnology BV announces that it licensed its 2G UNic™technology for boosting recombinant protein production to Eli Lilly and Company.

Under the agreement, Lilly gains non-exclusive commercial rights for application of the technology to the development of proprietary products. Financial details of the agreement were…